Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 8, 2009, Pages 2729-2734

  Kars, M ^a   Souverein, P C ^b   Herings, R M C ^c,d   Romijn, J A ^a   Vandenbroucke, J P ^a   De Boer, A ^b   Dekkers, O M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; PROLACTIN; QUINAGOLIDE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PARKINSON DISEASE; PHARMACY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; SEX DIFFERENCE;

EID: 68549118721     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0177     Document Type: Article

References (26)

1. Gillam MP, Molitch ME, Lombardi G, Colao A 2006 Advances in the treatment of prolactinomas. Endocr Rev 27:485-534
2. Schlechte JA 2003 Clinical practice. Prolactinoma. N Engl J Med 349:2035-2041
3. Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO 1985 Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60:698-705
4. Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G 1997 Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82:3574-3579
5. Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G 2000 Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247-2252
6. Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G 2009 Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord 10:111-123
7. Mancini T, Casanueva FF, Giustina A 2008. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37:67-99, viii
8. Faglia G 1993 Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinol (Copenh) 129(Suppl 1):1-5
9. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G 2003 Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148:325-331
10. Mindermann T, Wilson CB 1994 Age-related and gender-related occurrence of pituitary adenomas. Clin Endocrinol (Oxf) 41:359-364
11. Davis JR, Farrell WE, Clayton RN 2001 Pituitary tumours. Reproduction 121:363-371
12. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A 2006 High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769-4775
13. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, McCutcheon IE 2004 The prevalence of pituitary adenomas: a systematic review. Cancer 101:613-619
14. Lau HS, de Boer A, Beuning KS, Porsius A 1997 Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 50:619-625
15. van de Vijver DA, Stricker BH, Breteler MM, Roos RA, Porsius AJ, de Boer A 2001 Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease. Pharm World Sci 23:148-152
16. Ciccarelli A, Daly AF, Beckers A 2005 The epidemiology of prolactinomas. Pituitary 8:3-6
17. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, Elefante A, Cavallo LM, Briganti F, Cirillo S, Lombardi G 2007 Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) 67:426-433
18. Zwart JJ, Richters A, Ory F, de Vries JI, Bloemenkamp KW, van Roosmalen J 2008 Eclampsia in The Netherlands. Obstet Gynecol 112:820-827
19. Burdman JA, Pauni M, Heredia Sereno GM, Bordón AE 2008 Estrogen receptors in human pituitary tumors. Horm Metab Res 40:524-527
20. Maheux R, Jenicek M, Cleroux R, Beauregard H, De Muylder X, Gratton NM, Van Campenhout J 1982 Oral contraceptives and prolactinomas: a case-control study. Am J Obstet Gynecol 143:134-138
21. Jones JR, Kemmann E, Norwood PK 1981 Oral contraceptive exposure of amenorrheic women with and without prolactinomas. Int J Gynaecol Obstet 19:381-387
22. Shy KK, McTiernan AM, Daling JR, Weiss NS 1983 Oral contraceptive use and the occurrence of pituitary prolactinoma. JAMA 249:2204-2207
23. Thorner MO, McNeilly AS, Hagan C, Besser GM 1974 Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J 2:419-422
24. Miyai K, Ichihara K, Kondo K, Mori S 1986 Asymptomatic hyperprolactinaemia and prolactinoma in the general population: mass screening by paired assays of serum prolactin. Clin Endocrinol (Oxf) 25:549-554
25. Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH 1998 Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73:1046-1052
26. Schaller B 2005 Gender-related differences in prolactinomas. A clinicopathological study. Neuro Endocrinol Lett [Erratum (2005) 26:628] 26:152-159